Bharat Biotech International Limited is a pioneering multi-dimensional biotechnology company headquartered in Hyderabad, India. Specializing in R&D, manufacturing, and marketing of innovative vaccines and biotherapeutics, Bharat Biotech is committed to advancing global health. The company is globally recognized for its contributions, including the development of COVAXIN®, India's first indigenous COVID-19 vaccine. Their portfolio includes vaccines for diseases like Rotavirus, Typhoid, Hepatitis B, Polio, Rabies, and Japanese Encephalitis. Bharat Biotech strives to make healthcare solutions accessible and affordable, driven by a strong focus on innovation and quality.
Serves as the company's primary hub for research and development, large-scale manufacturing of vaccines and biopharmaceuticals, and corporate operations.
Located in Genome Valley, Asia's premier biotech cluster. State-of-the-art BSL-3 (Bio-Safety Level 3) manufacturing facilities for viral vaccines and advanced research laboratories.
Highly research-oriented, innovative, and quality-focused. Emphasis on scientific rigor, collaboration, and addressing public health needs. Fast-paced environment driven by breakthroughs and manufacturing excellence.
Central to India's biopharmaceutical self-reliance, particularly highlighted by its role in developing and manufacturing COVAXIN®. A key node in the global vaccine supply chain and a symbol of indigenous innovation.
Bharat Biotech supports global health initiatives through the development and supply of affordable vaccines to over 125 countries worldwide. Their global presence is marked by product registrations in numerous nations, partnerships with international organizations like WHO, GAVI, UNICEF, Pan American Health Organization (PAHO), and collaborations with research institutions globally. They actively participate in global efforts to combat infectious diseases by exporting vaccines, engaging in technology transfers, and contributing to international public health programs.
Genome Valley, Turkapally (Village), Shameerpet (Mandal)
Hyderabad
Telangana
India
Address: Chiron Behring Vaccines Pvt. Ltd. (A Bharat Biotech Company), Plot No. 30, GIDC Indl. Estate, Ankleshwar, Gujarat - 393002, India
Strategic location in a major industrial estate in Gujarat, contributing to the overall manufacturing footprint, supply chain diversification, and capacity for vaccine production in India.
Address: c/o Bio-Vet Pvt. Ltd. (Subsidiary of Bharat Biotech), KIADB Industrial Area, Malur, Kolar District, Karnataka, India
Provides essential infrastructure for cutting-edge vaccine research and development, particularly for studies requiring specialized bio-safety levels and animal models, supporting national biosecurity and pandemic preparedness efforts.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Bharat Biotech ' leadership includes:
Bharat Biotech has been backed by several prominent investors over the years, including:
No major, publicly announced changes in the top executive team (Chairman, JMD, key C-level/Department Heads) have been widely reported for Bharat Biotech International Limited in the last 12 months (as of early 2024). The company has largely maintained stability in its core leadership. Minor changes or appointments at other management levels may have occurred but are not typically disclosed publicly in detail.
Discover the tools Bharat Biotech uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Bharat Biotech International Limited likely utilizes standard corporate email formats. Based on common patterns observed in the industry and for similar organizations, the most probable format involves a combination of the employee's first name initial and last name.
[firstinitial][lastname]@bharatbiotech.com
Format
kella@bharatbiotech.com
Example
75%
Success rate
The Hindu BusinessLine / WHO • January 19, 2024
Bharat Biotech announced that its oral rotavirus vaccine, Rotavac 5D®, has received Prequalification from the World Health Organization (WHO). This significant milestone enables its procurement by UN agencies like UNICEF and GAVI for global public health vaccination programs, thereby expanding access to this crucial vaccine against rotavirus diarrhea, a leading cause of severe childhood illness....more
BioSpectrum Asia / Company Press Release • November 15, 2023
Bharat Biotech has commenced Phase III clinical trials for its Chikungunya vaccine candidate, BBV87, in Costa Rica, in collaboration with the International Vaccine Institute (IVI). This marks a significant step towards developing a safe and effective vaccine for the mosquito-borne disease, which currently has no specific antiviral treatment and poses a considerable public health challenge in many regions....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Bharat Biotech , are just a search away.